A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 3, 2009, Pages 248-253

  Bussamra, Maria H ^a   Stelmach, Rafael ^a   Rodrigues, Joaquim C ^a   Cukier, Alberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; PREDNISOLONE; TERBUTALINE;

ADOLESCENT; ARTICLE; ASTHMA; BREATHING RATE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRY POWDER; EMERGENCY CARE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; POWDER INHALER; PRIORITY JOURNAL; PULSE OXIMETER; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPIROMETRY;

EID: 70349462584     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60189-5     Document Type: Article

References (34)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention 2007 (update). http://ginasthma.com. Accessed October 2008.
2. Tattersfield AE, Lofdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet. 2001;357:257-261.
3. Pauwels RA, Sears MR, Campbell M, et al; RELIEF study investigators. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J. 2003;22:787-794.
4. Ind PW, Villasante C, Shiner RJ, et al. Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma. Eur Respir J. 2002;20:859-866. (Pubitemid 35175121)
5. McFadden ER Jr. Acute severe asthma. Am J Respir Crit Care Med. 2003;168:740-759.
6. Foucard T, Lonnerholm G. A study with cumulative doses of formoterol and salbutamol in children with asthma. Eur Respir J. 1991;4: 1174-1177.
7. Wallin A, Sandstrom T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax. 1993;48:611-614. (Pubitemid 23188434)
8. Bartow RA, Brogden RN. Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthma [published correction appears in Drugs. 1998;55:517]. Drugs. 1998;55: 303-322.
9. Totterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J. 1998;12:573-579. (Pubitemid 28420133)
10. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 2000;55:650-656. (Pubitemid 30468219)
11. Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med. 2003;97: 1067-1074. (Pubitemid 37098773)
12. Lee-Wong M, Chou V, Ogawa Y. Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. Ann Allergy Asthma Immunol. 2008;100:146-152. (Pubitemid 351238550)
13. Becker AB, Nelson NA, Simons FE. The pulmonary index: assessment of a clinical score for asthma. Am J Dis Child. 1984;138:574-576.
14. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144: 1202-1218.
15. Polgar G, Weng TR. The functional development of the respiratory system from the period of gestation to adulthood. Am Rev Respir Dis. 1979;120:625-695. (Pubitemid 10230205)
16. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127:725-734.
17. Bussamra MH, Cukier A, Stelmach R, Rodrigues JC. Evaluation of the magnitude of the bronchodilator response in children and adolescents with asthma. Chest. 2005;127:530-535. (Pubitemid 40229313)
18. Lotvall J, Mellen A, Arvidsson P, et al. Similar bronchodilation with formoterol delivered by aerolizer or Turbuhaler. Can Respir J. 1999;6: 412-416. (Pubitemid 29537467)
19. Sears MR. The evolution of β2-agonists. Respir Med. 2001;95(suppl B):S2-6.
20. Najafizadeh K, Pour HS, Ghadyanee M, Shiehmorteza M, Jamali M, Majdzadeh S. A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma. Emerg Med J. 2007;24:317-321. (Pubitemid 46696352)
21. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lotvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol. 2000;56:363-370. (Pubitemid 30666061)
22. Bisgaard H. Effect of long-acting β2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol. 2003;36:391-398. (Pubitemid 37296699)
23. Newhouse MT. Asthma therapy with aerosols: are nebulizers obsolete? a continuing controversy. J Pediatr. 1999;135:5-8.
24. De Boeck K, Alifier M, Warnier G. Is the correct use of a dry powder inhaler (Turbuhaler) age dependent? J Allergy Clin Immunol. 1999;103: 763-767. (Pubitemid 29297576)
25. Bronsky EA, Grossman J, Henis MJ, et al. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Curr Med Res Opin. 2004;20:131-137. (Pubitemid 38197313)
26. Waldeck B. Some pharmacodynamic aspects on long-acting β-adrenoceptor agonists. Gen Pharmacol. 1996;27:575-580. (Pubitemid 26233323)
27. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2001;(1):CD000195.
28. Hospenthal MA, Peters JI. Long-acting β(2)-agonists in the management of asthma exacerbations. Curr Opin Pulm Med. 2005;11:69-73. (Pubitemid 40189254)
29. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129:246-256. (Pubitemid 43289841)
30. Cheer SM, Warner GT, Easthope SE. Formoterol delivered by Turbuhaler: in pediatric asthma. Paediatr Drugs. 2003;5:63-68. (Pubitemid 36127027)
31. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129-136. (Pubitemid 40105411)
32. Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006;130:1733-1743. (Pubitemid 46033427)
33. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124:70-74. (Pubitemid 36851333)
34. Taylor DR, Hancox RJ, McRae W, et al. The influence of polymorphism at position 16 of the β2-adrenoceptor on the development of tolerance to β-agonist. J Asthma. 2000;37:691-700. (Pubitemid 32042824)